Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - CEO, President & Director Mardi Dier - CFO & Senior VP Conference Call Participants Thomas Smith - Leerink Partners Andrea Tan - Goldman Sachs Andy Chen - Wolfe Research Eliana Merle - UBS Yasmeen Rahimi - Piper Sandler Ritu Baral - TD Cowen David Lebowitz - Citi Jon Wolleben - Citizens JMP Operator Good day, and thank you f ...

Madrigal (MDGL) came out with a quarterly loss of $7.10 per share versus the Zacks Consensus Estimate of a loss of $7.55. This compares to loss of $4.69 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.96%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $6.06 per share when it actually produced a loss of $7.38, delivering a surprise of -21.78%. Over the last four quarters, the company ...

Table of Contents _________________________ _________________________ _________________________ _________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates • Second-quarter 2024 net sales of $14.6 million • Rezdif ra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdif ra-covered lives require biopsy • Expert guidelines recommend Rezdif ra as first-line therapy for patients with F2/F3 NASH/MASH • Plans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025 ...

Second-quarter 2024 net sales of $14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require biopsy Expert guidelines recommend Rezdiffra as first-line therapy for patients with F2/F3 NASH/MASH Plans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025 Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion at June 30, 2024 Company to host ...

Will being the first to its market ensure that its future is bright? With shares of Madrigal Pharmaceuticals (MDGL -1.12%) up by 220% over the last three years, it's easy to see why investors might get the idea that there isn't much upside left with this biotech stock. Without much in the way of media buzz, its future accomplishments, assuming there are any, might not even get noticed by the market -- so the argument goes. But is it actually too late to buy this stock, or is there still an opportunity? Taki ...

CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief ...

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com. The webcast will be available approximately two hours after the live webcast. Following the announcement, Madrigal's ma ...

With such a favorable setup, could it be the case that an investment in it made today would lead to building wealth on the scale of $1 million? It's not as unlikely as it sounds, so let's look at the details. First, the value of the stock would need to go up by a vast amount over the next decade or two, likely on the order of 10 to 20 times. Second, the investor would need to have committed sufficient capital for that multiplicative growth to yield at least $1 million. In the case of the stock rising by 10X ...

Madrigal Pharmaceuticals (MDGL 0.21%) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. It'll be growing, and likely quickly While Rezdiffra is only indicated to treat patients with moderate-to-severe fibrosis (scarring) of the liver, the company plans to continue with its research and development (R&D) activities to test its helpfulness in the context of m ...